[go: up one dir, main page]

Von Hoff et al., 1980 - Google Patents

Phase I clinical investigation of 1, 4-dihydroxy-5, 8-bis {{{2-[(2-hydroxyethyl) amino] ethyl} amino}}-9, 10-anthracenedione dihydrochloride (NSC 301739), a new …

Von Hoff et al., 1980

Document ID
578804573878577388
Author
Von Hoff D
Pollard E
Kuhn J
Murray E
Coltman Jr C
Publication year
Publication venue
Cancer Research

External Links

Snippet

Dihydroxy-5, 8-bis {{{2-[(2-hydroxyethyl) amino] ethyl}-amino}}-9, 10-anthracenedione dihydrochloride is a new anthracenedione derivative that was evaluated in a Phase I clinical trial. The schedule of administration consisted of a single iv injection, repeated at 4-week …
Continue reading at aacrjournals.org (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (-N=N-), diazo (=N2), azoxy (>N-O-N< or N(=O)-N<), azido (-N3) or diazoamino (-N=N-N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations

Similar Documents

Publication Publication Date Title
Von Hoff et al. Phase I clinical investigation of 1, 4-dihydroxy-5, 8-bis {{{2-[(2-hydroxyethyl) amino] ethyl} amino}}-9, 10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione
KR100638684B1 (en) 9-deoxy-2 &#39;, 9-alpha-methano-3-oxa-4,5,6-trinor-3,7- (1&#39;, 3&#39;-interphenylene) for the treatment of peripheral vascular disease Use of -13,14-dihydro-prostaglandin F1
US5225404A (en) Methods of treating colon tumors with tumor-inhibiting camptothecin compounds
US6537990B1 (en) Combined preparations comprising morpholine anthracyclines and anticancer agent
Von Hoff et al. Phase I clinical investigation of 9, 10-anthracenedicarboxaldehyde bis [(4, 5-dihydro-1 H-imidazol-2-yl) hydrazone] dihydrochloride (CL216, 942)
DE69322251T2 (en) MEDICAL COMPOSITION
US5049396A (en) Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer sensitive to treatment
WO1999048503A1 (en) Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate
CA2286557A1 (en) Phorbol esters as anti-neoplastic agents
NL8301913A (en) AGENT FOR STRENGTHENING THE ANTITUMOR ACTIVITY OF AN AGENT AGAINST TUMORS.
Van Echo et al. Phase I clinical and pharmacological study of 4′-(9-acridinylamino)-methanesulfon-m-anisidide using an intermittent biweekly schedule
Cortes et al. Adriamycin in advanced bronchogenic carcinoma
Berger et al. Influence of the alkyllysophospholipid ET-18-OCH3 on methylnitrosourea-induced rat mammary carcinomas
US6365578B1 (en) Drug cominbations containing AZT
Tullis Triethylenephosphoramide in the treatment of disseminated melanoma
Harvey et al. Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer
Vogler Phase I Study of Twice Weekly 5-Azacytidine (NSC-102816) William Ralph Vogler, Sureyya Arkun, and Enrique Velez-Garcia 4, 5 Writing Committee for the Southeastern Cancer Study Group
DE69121551T2 (en) ANTINEOPLASTICALLY ACTIVE AND STRENGTHENING ANTINEOPLASTIC EFFECT
US4343799A (en) Use of derivatives of 6α-methylprednisolone for the prevention or reduction of adriamycin-induced cardiotoxicity
O'Connell et al. Phase II clinical trial of tricyclic nucleoside phosphate for advanced colorectal cancer.
Nichols et al. Phase II Trial of Indicine N-Oxide (INDI) in Patients
Broder et al. 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, NSC-79037): a comparison of drug administration at four-week and six-week intervals
Gottlieb et al. An evaluation of large intermittent intravenous doses of cyclophosphamide (NSC-26271) in the treatment of metastatic malignant melanoma
Mouridsen et al. Mitoxantrone as first line cytotoxic therapy in advanced breast cancer: preliminary results of a phase II study
Maral et al. Phase II evaluation of diaziquone (CI-904, AZQ) in the treatment of human malignant glioma